CervoMed (NASDAQ:CRVO – Get Free Report) and Pathfinder Cell Therapy (OTCMKTS:PFND – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.
Institutional and Insider Ownership
25.2% of CervoMed shares are owned by institutional investors. 35.4% of CervoMed shares are owned by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares CervoMed and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CervoMed | -672.80% | -136.08% | -112.62% |
| Pathfinder Cell Therapy | N/A | N/A | N/A |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CervoMed | $4.01 million | 6.86 | -$26.97 million | ($3.28) | -0.91 |
| Pathfinder Cell Therapy | N/A | N/A | N/A | N/A | N/A |
Pathfinder Cell Therapy has lower revenue, but higher earnings than CervoMed.
Analyst Ratings
This is a summary of current recommendations and price targets for CervoMed and Pathfinder Cell Therapy, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CervoMed | 1 | 1 | 6 | 0 | 2.63 |
| Pathfinder Cell Therapy | 0 | 0 | 0 | 0 | 0.00 |
CervoMed currently has a consensus target price of $22.60, suggesting a potential upside of 660.94%. Given CervoMed’s stronger consensus rating and higher probable upside, equities analysts plainly believe CervoMed is more favorable than Pathfinder Cell Therapy.
Summary
CervoMed beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.
About CervoMed
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
About Pathfinder Cell Therapy
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
